<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RITUXIMAB</span><br/>(rit-ux'i-mab)<br/><span class="topboxtradename">Rituxan<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">immunomodulator</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Genetically engineered monoclonal antibody that binds with the CD20 antigen on the surface of normal and malignant B lymphocytes.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Administration of drug results in a rapid and sustained depletion of circulating and tissue-based (e.g., thymus, spleen) B
         lymphocytes in non-Hodgkin's lymphoma.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Relapsed or refractory CD20 positive, B-cell non-Hodgkin's lymphoma.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to murine proteins, rituximab, or abciximab; angina, cardiac arrhythmias, cardiac disease; pulmonary disease,
         chronic lymphocytic leukemia (CLL), lymphoma, severe hypotension; oliguria, rising serum creatinine; viral hepatitis B (HBV),
         vaccination; pregnancy (category C), lactation, children.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Prior exposure to murine-based monoclonal antibodies; history of allergies; asthma and other pulmonary disease (increased
         risk of bronchospasm); respiratory insufficiency; CAD; thrombocytopenia; history of cardiac arrhythmias; hypertension, renal
         impairment. Safety and efficacy in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Non-Hodgkin's Lymphoma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 375 mg/m<sup>2</sup> infused at 50 mg/h, may increase infusion rate q30min (max: 400 mg/h if tolerated), repeat dose on days 8, 15, and 22 (total
               of 4 doses)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute ordered dose to 14 mg/mL by adding to an infusion bag of NS or D5W. Examples: 500 mg in 400 mL yields 1 mg/mL;
                  500 mg in 75 mL yields 4 mg/mL. Gently invert bag to mix. Discard unused portion left in vial.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse first dose at a rate of 50 mg/h; may increase rate at 50 mg/h increments q30min to maximum rate of 400 mg/h. For subsequent
                  doses, infuse at a rate of 100 mg/h and increase by 100 mg/h increments q30min up to maximum rate of 400 mg/h.  
               </p>
<ul>
<li>Slow or stop infusion if S&amp;S of hypersensitivity appear (see Appendix F).</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store unopened vials at 2°8° C (36°46° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Angioedema, <span class="speceff-common">fatigue,</span> asthenia, night sweats, <span class="speceff-common">fever, chills,</span> myalgia. <span class="typehead">CNS:</span> Headache, dizziness, depression. <span class="typehead">CV:</span> Hypotension, tachycardia, peripheral edema. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> vomiting, throat irritation, anorexia, abdominal pain, hepatitis B reactivation with <span class="speceff-life">fulminant hepatitis,</span> <span class="speceff-life">hepatic failure, and death</span>.  <span class="typehead">Hematologic:</span> <span class="speceff-life">Leukopenia, thrombocytopenia, anemia, neutropenia</span>. <span class="typehead">Respiratory:</span> Bronchospasm, dyspnea, rhinitis. <span class="typehead">Skin:</span> Pruritus, rash urticaria. <span class="typehead">Other:</span> Infusion-related reactions: <span class="speceff-common">Fever, chills, rigors, pruritus, urticaria, pain, flushing</span>, chest pain, hypotension, hypertension, dyspnea; <span class="speceff-life">fatal infusion-related reactions</span> have been reported. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">antihypertensive agents</span> should be stopped 12 h prior to rituximab to avoid excessive hypotension; <b>cisplatin</b> may cause additive nephrotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Duration:</span> 612 mo. <span class="typehead">Half-Life:</span> 60174 h (increases with multiple infusions). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: CBC with differential, peripheral CD20+ B lymphocytes.</li>
<li>Monitor carefully BP and ECG status during infusion and immediately report S&amp;S of hypersensitivity (e.g., fever, chills, urticaria,
            pruritus, hypotension, bronchospasms; see Appendix F for others).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not take antihypertensive medication within 12 h of rituximab infusions.</li>
<li> 							Note: Use effective contraception during and for up to 12 mo following rituximab therapy. 						</li>
<li>Report any of the following experienced during infusion: itching, difficulty breathing, tightness in throat, dizziness, headache,
            nausea.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>